{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-276691","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2026-06-22T11:08:42+00:00","discovered_at":"2026-06-22T11:10:00.273914+00:00","generated_at":"2026-06-22T11:10:32.089477+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MapLight's ML-004 Phase 2 misses primary endpoint in autism; shows signal in adolescent irritability","bullets":["Primary endpoint (ABI-Social Communication) not met in Phase 2 IRIS trial of ML-004 in ASD.","Adolescents with baseline ABC-I≥16 showed improvement (ES=1.33, p=0.013) on ABC-I and CGI-I irritability (ES=1.08, p=0.036).","ML-004 well-tolerated; no severe/serious AEs in active arm, no extrapyramidal events, weight gain lower than placebo.","Company to engage FDA for End-of-Phase 2 meeting; Phase 2 ZEPHYR (schizophrenia) topline due mid-Aug 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-276691","json":"https://secwatch.observer/filing/0001193125-26-276691.json","markdown":"https://secwatch.observer/filing/0001193125-26-276691.md","text":"https://secwatch.observer/filing/0001193125-26-276691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/0001193125-26-276691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526276691/d31456d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:10:32.089477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}